Goldman Sachs’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-218,143
| Closed | -$22.2M | – | 5998 |
|
|
2023
Q2 | $22.2M | Buy |
218,143
+75,344
| +53% | +$7.13M | ﹤0.01% | 1759 |
|
|
2023
Q1 | $13M | Sell |
142,799
-130,419
| -48% | -$7.65M | ﹤0.01% | 2185 |
|
|
2022
Q4 | $10.4M | Sell |
273,218
-74,512
| -21% | -$2.56M | ﹤0.01% | 2553 |
|
|
2022
Q3 | $8.74M | Buy |
347,730
+271,475
| +356% | +$7.52M | ﹤0.01% | 2635 |
|
|
2022
Q2 | $2.32M | Sell |
76,255
-31,102
| -29% | -$928K | ﹤0.01% | 3916 |
|
|
2022
Q1 | $3.52M | Sell |
107,357
-1,075,213
| -91% | -$31.9M | ﹤0.01% | 3684 |
|
|
2021
Q4 | $31.2M | Buy |
1,182,570
+1,005,161
| +567% | +$77.8M | 0.01% | 1736 |
|
|
2021
Q3 | $17.8M | Buy |
177,409
+115,525
| +187% | +$13.5M | ﹤0.01% | 2176 |
|
|
2021
Q2 | $8.76M | Sell |
61,884
-169,867
| -73% | -$19.2M | ﹤0.01% | 2818 |
|
|
2021
Q1 | $23.1M | Sell |
231,751
-1,473
| -0.6% | -$172K | 0.01% | 1821 |
|
|
2020
Q4 | $28.8M | Sell |
233,224
-76,386
| -25% | -$10M | 0.01% | 1555 |
|
|
2020
Q3 | $30.2M | Buy |
309,610
+29,121
| +10% | +$3.64M | 0.01% | 1407 |
|
|
2020
Q2 | $43.8M | Buy |
280,489
+108,047
| +63% | +$16.4M | 0.01% | 1055 |
|
|
2020
Q1 | $24.9M | Buy |
172,442
+10,424
| +6% | +$2.01M | 0.01% | 1359 |
|
|
2019
Q4 | $33.1M | Buy |
162,018
+32,521
| +25% | +$5.93M | 0.01% | 1456 |
|
|
2019
Q3 | $10.4M | Buy |
129,497
+50,363
| +64% | +$4.27M | ﹤0.01% | 2298 |
|
|
2019
Q2 | $7.47M | Sell |
79,134
-3,269
| -4% | -$282K | ﹤0.01% | 2579 |
|
|
2019
Q1 | $7.04M | Buy |
82,403
+38,632
| +88% | +$3.21M | ﹤0.01% | 2712 |
|
|
2018
Q4 | $2.46M | Buy |
43,771
+19,390
| +80% | +$1.18M | ﹤0.01% | 3401 |
|
|
2018
Q3 | $1.99M | Sell |
24,381
-5,909
| -20% | -$416K | ﹤0.01% | 3609 |
|
|
2018
Q2 | $1.06M | Buy |
30,290
+818
| +3% | +$24.9K | ﹤0.01% | 4031 |
|
|
2018
Q1 | $604K | Buy |
29,472
+18,623
| +172% | +$479K | ﹤0.01% | 4371 |
|
|
2017
Q4 | $307K | Buy |
+10,849
| New | +$303K | ﹤0.01% | 5165 |
|
|
2016
Q4 | – | Sell |
-8,542
| Closed | -$225K | – | 7150 |
|
|
2016
Q3 | $225K | Sell |
8,542
-46,562
| -84% | -$924K | ﹤0.01% | 5729 |
|
|
2016
Q2 | $1.09M | Buy |
+55,104
| New | +$1.07M | ﹤0.01% | 4117 |
|
Other funds holding RETA
Goldman Sachs's RETA Position: Q3 2023 in Review
Goldman Sachs sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 218,143 shares — an estimated $22.2M sold.
Goldman Sachs first reported a position in RETA in Q2 2016 and held it in 25 quarters. The position peaked at $43.8M in Q2 2020. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Goldman Sachs reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Goldman Sachs sold 218,143 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $22.2M.
- Goldman Sachs first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 25 quarters.
- Goldman Sachs's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $43.8M in Q2 2020.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.